| Identification | Back Directory | [Name]
(S)-1-CYCLOHEXYL-4-[4-(2-METHOXY-PHENYL)-PIPERAZIN-1-YL]-2-PHENYL-BUTAN-1-ONE | [CAS]
228418-82-4 | [Synonyms]
LY426965, S-(+)-
(S)-1-CYCLOHEXYL-4-[4-(2-METHOXY-PHENYL)-PIPERAZIN-1-YL]-2-PHENYL-BUTAN-1-ONE
(S)-1-Cyclohexyl-4-(4-(2-methoxyphenyl)piperazin-1-yl)-2-methyl-2-phenylbutan-1-one
1-BUTANONE, 1-CYCLOHEXYL-4-[4-(2-METHOXYPHENYL)-1-PIPERAZINYL]-2-METHYL-2-PHENYL-, (2S)-
1-CYCLOHEXYL-4-[4-(2-METHOXYPHENYL)-1-PIPERAZINYL]-2-METHYL-2-PHENYL-1-BUTANONE, (S)-(+)- | [Molecular Formula]
C28H38N2O2 | [MDL Number]
MFCD10565913 | [MOL File]
228418-82-4.mol | [Molecular Weight]
434.61 |
| Hazard Information | Back Directory | [Uses]
LY426965 is a potent arylpiperazine compound known for its role as a full antagonist of the serotonin 1A receptor, lacking partial agonist activity. It is identified as a selective 5-HT1A antagonist, showing promise in preclinical studies for treating conditions associated with serotonin dysregulation, such as smoking cessation and depression-related disorders[1]. | [References]
[1] Asymmetric Construction of Quaternary Centers by Enantioselective Allylation: Application to the Synthesis of the Serotonin Antagonist LY426965 |
|
|